ARCHIVES

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

This article is from The Cancer Letter archive.

Vol. 40 No. 06 | February 7, 2014

Download PDF Visit The Full Archive

Related Articles

Avastin Vote Puts Focus On FDA Criteria In First-Line Metastatic Breast Cancer: Is PFS Good Enough?

December 14, 2007

New Agent Targets Glioma Tumor Cells Prior To Surgery

May 30, 2003

New Core Gant Guideline Proposals Drawn Up; Opposition Developing Among Center Directors

April 4, 1980

Becker, Brown Testify On Biomedical Funding, Manpower Needs

March 23, 1990

Cancer Policy: New Cancer Board to Take A Year to Conduct First Study

April 18, 1997

NCI Announces Designation Of Comprehensive Center

July 20, 1990